Abstract:Abstract Background Rapamycin is known to be effective in suppressing senescence and the senescence-associated secretory phenotype (SASP). Therefore, it is highly expected to represent an anti-aging drug. Its anti-aging effect has been demonstrated at the mouse individual level. However, there are not many clinical findings with respect to its activity in humans. Here, we aimed to clarify the effect of rapamycin on human endothelial cells (ECs) as an in vitro model of human blood vessels. Methods Over the course of oxidative stress-induced senescence using hydrogen peroxide, we examined the effect of rapamycin on human coronary artery ECs (HCAECs). Senescence was evaluated by detecting senescence-associated β-galactosidase (SA-β-Gal) activity and the real-time PCR analysis of p16 INK4a . Furthermore, expression levels of SASP factors were examined by real-time PCR and the expression of senescence-related antigens, such as intercellular adhesion molecule-1 (ICAM-1) and ganglioside GM1, were examined by fluorescence-activated cell sorting analysis and immunostaining. The inhibitory effect of rapamycin on mTOR signaling was examined by immunoblotting. The adhesion of leukocytes to HCAECs was evaluated by adhesion assays. Endothelial–mesenchymal transition (EndMT) induced by rapamycin treatment was evaluated by real-time PCR analysis and immunostaining for EndMT markers. Finally, we checked the activation of autophagy by immunoblotting and examined its contribution to EndMT by using a specific inhibitor. Furthermore, we examined how the activation of autophagy influences TGF-β signaling by immunoblotting for Smad2/3 and Smad7. Results A decrease in SA-β-Gal activity and the suppression of SASP factors were observed in HCAECs undergoing stress-induced premature senescence (SIPS) after rapamycin treatment. In contrast, ICAM-1 and ganglioside GM1 were upregulated by rapamycin treatment. In addition, leukocyte adhesion to HCAECs was promoted by this treatment. In rapamycin-treated HCAECs, morphological changes and the promotion of EndMT were also observed. Furthermore, we found that autophagy activation induced by rapamycin treatment, which led to activation of the TGF-β pathway, contributed to EndMT induction. Conclusions We revealed that although rapamycin functions to inhibit senescence and suppress SASP in HCAECs undergoing SIPS, EndMT is induced due to the activation of autophagy.

Cell senescence, rapamycin and hyperfunction theory of aging

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

From rapalogs to anti-aging formula

mTOR and Aging: An Old Fashioned Dress

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership

The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling

A comprehensive model for the biochemistry of ageing, senescence and longevity

Senescent cells: SASPected drivers of age-related pathologies

The mTORC1-autophagy pathway is a target for senescent cell elimination

Suppression of replicative senescence by rapamycin in rodent embryonic cells

The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging

Uncharacterized yeast gene YBR238C , an effector of TORC1 signaling in a mitochondrial feedback loop, accelerates cellular aging via HAP4 - and RMD9 -dependent mechanisms

Uncoupling of mTORC1 from E2F activity maintains DNA damage and senescence

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion

Rapalink-1 reveals novel mTOR-dependent genes and an agmatinergic axis-based metabolic feedback regulating mTOR activity and lifespan

Rapamycin promotes endothelial–mesenchymal transition during stress-induced premature senescence through the activation of autophagy

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

mTORC2: A neglected player in aging regulation

Effects of Rapamycin Induced Cellular Autophagy in Aging-Related Diseases

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy